NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment
Rhea-AI Summary
NEXGEL (NASDAQ: NXGL) closed the license and acquisition of Celularity's commercial-stage regenerative biomaterials portfolio and launched BioNX Surgical. The deal is led by a $5.5 million strategic investment from Sequence LifeScience™ and financed via a convertible note with a $0.60 conversion price and 50% warrant coverage. The transaction is expected to approximately triple pro-forma annual revenue to about $35 million and be immediately accretive to profitability, adding 6 established products with existing reimbursement and accelerating commercialization.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Pro-forma revenue ~ $35M (approximately triple current annual revenue)
- $5.5M strategic investment from Sequence LifeScience™ to lead the financing
- 6 acquired commercial products with over a decade of clinical use and reimbursement
- Immediate accretion to profitability and attractive gross margins reported
Negative
- Convertible note financing with $0.60 conversion price and 50% warrant coverage (potential dilution)
News Market Reaction – NXGL
On the day this news was published, NXGL gained 15.89%, reflecting a significant positive market reaction. Argus tracked a peak move of +27.3% during that session. Argus tracked a trough of -6.4% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $996K to the company's valuation, bringing the market cap to $7.26M at that time. Trading volume was exceptionally heavy at 5.4x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 17 | Call timing update | Neutral | -1.5% | Moved shareholder update call on Celularity transaction to April 21 at 4:30 P.M. |
| Apr 15 | Call reschedule, financing | Neutral | -15.3% | Rescheduled shareholder call and disclosed shift to new investor financing group. |
| Apr 08 | Call reschedule, financing | Neutral | -2.7% | Rescheduled Celularity update call; noted no assurance of closing and new financing talks. |
| Mar 31 | Earnings call reschedule | Neutral | -1.3% | Rescheduled 2025 results call to add detail on proposed Celularity transaction. |
| Mar 25 | Earnings date set | Neutral | -1.0% | Announced timing of Q4 and full-year 2025 results and related conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Celularity-related scheduling and update headlines have been followed by modest negative price reactions despite neutral tone.
Over the last month, NEXGEL news focused on rescheduling shareholder and earnings calls to provide more detail on the proposed Celularity transaction, with events on Mar 25, Mar 31, Apr 8, Apr 15, and Apr 17. Each update mainly adjusted call logistics or financing structure and carried neutral summaries, yet the stock posted small declines after each release. Today’s closing of the Celularity degenerative disease segment acquisition and new financing marks a concrete step following that series of process updates.
Key Terms
convertible note financial
warrant coverage financial
510(k) regulatory
contract manufacturer technical
HCT/P medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Transaction expected to approximately triple NEXGEL’s annual revenue to approximately
Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028
Forms BioNX Surgical, a division of NEXGEL
LANGHORNE, Pa. , April 21, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the closing of its previously announced license and acquisition of a portfolio of commercial-stage regenerative biomaterials products from Celularity Inc. (NASDAQ: CELU), a regenerative and cellular medicine company. The Company has also launched BioNX Surgical, a new division of NEXGEL.
The closing of this transaction will be financed under new terms and led by a
“We are pleased to partner with Sequence LifeScience™, to lead this financing round and support the closing of our transaction,” said Adam Levy, Chief Executive Officer of NEXGEL. “This marks a transformative moment for NEXGEL. With this transaction now complete we have strengthened our financial structure, expanded our commercial capabilities, and created new opportunities for product development. We believe we are now well positioned to accelerate growth, enhance margins, and deliver long-term value for our shareholders.”
Sequence will serve as a contract manufacturer for NEXGEL/BioNX. The companies also plan to collaborate on the development of additional new products leveraging Sequence’s expertise and NEXGEL’s hydrogel technology. Sequence’s investment and ongoing role as a strategic partner align manufacturing, product development, and commercialization capabilities, while supporting future pipeline expansion, including the planned 510(k) filings in 2026, 2027, and 2028.
The transaction establishes NEXGEL as an emerging platform in regenerative medicine through the formation of BioNX Surgical, a dedicated division focused on advanced biomaterials for tendon repair, soft tissue reconstruction, and bone regeneration. The acquired portfolio includes 6 established products with over a decade of clinical use and existing reimbursement coverage, positioning the Company for accelerated commercial expansion and near-term revenue scale.
The transaction is expected to approximately triple NEXGEL’s annual revenue to approximately
Brian Kieser, Chief Executive Officer of Sequence LifeScience™, added, “One of our core principles at Sequence LifeScience™ is that we ‘partner to multiply impact,’ and NEXGEL is a strong strategic fit. Our advanced HCT/P processing and product innovation capabilities complement NEXGEL’s technology platforms and established sales and distribution channels accelerating development, expanding market reach, and supporting scalable product expansion. Together, we are well positioned to drive meaningful growth for both organizations.”
The Company will host a shareholder update call today to discuss the Celularity transaction and its new strategic partnership with Sequence LifeScience™.
Shareholder Update Call Details:
Date: April 21, 2026
Time: 4:30 P.M. ET
Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)
Webcast: Events and Presentations
About NEXGEL, Inc.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
About Sequence Life Sciences
Sequence™ is a global life sciences company advancing healing through the ethical manufacturing and distribution of high-quality human tissue products. Our brand is built on decades of combined expertise in tissue banking, regenerative biologics, orthopedic innovation, and quality systems. Every product we manufacture reflects our commitment to the donors who made it possible and the patients who depend on it. www.sequencelifesci.com
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “attempt,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our expectation that the transaction will approximately triple NEXGEL’s annual revenue to about
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
